Collectively, these findings identify TIPE2 as an immune-relevant biomarker candidate with prognostic significance across various cancers and warrant further mechanistic and clinical validation to elucidate its potential role in immunotherapy-based patient stratification. Here, TIPE2 is linked to cancer.